16 results about "Protein S level" patented technology

Provided herein are methods, compositions, and kits for treating an HBV infection comprising administering to a subject an siRNA specific for an HBV target and an antisense oligonucleotide specific for an HBV target. The methods, compositions, and kits provided herein reduce HBV DNA, HBV mRNA, and HBV protein levels in the subject.

The present application belongs to the technical field of biomedicine, and provides a pharmaceutical composition for inhibiting NFKBIZ gene expression, and a use. The present application designs a double-stranded nucleic acid molecule capable of targeting and regulating NFKBIZ gene expression. By means of verifying the gene regulation efficiency of nucleic acid molecules, multiple nucleic acid molecules capable of inhibiting NFKBIZ gene expression are obtained from screening, and efficient inhibition of IκB-ζ protein expression is achieved at the protein level. In addition, the present application verifies a use of a pharmaceutical composition formed by the conjugation of the described nucleic acid molecules and targeting ligand molecules in ophthalmic diseases. The pharmaceutical composition can solve the problems with existing small molecule immunomodulatory drugs of low delivery efficiency and poor therapeutic effect, providing small nucleic acid drugs having tissue-targeted delivery functions, and has the advantages of long duration of efficacy and low side effects. In addition, the pharmaceutical composition has simple ingredients, is easy to synthesize, and has good prospects for translational applications.

Proteases of Group IV (+)ssRNA viruses were found to act on a human sequences in addition to the viral sequences. The identity of the cleavable human sequences is disclosed. Detection of these sequences can act as a diagnostic of infection. It is contemplated that these findings could be employed to facilitate post-translational silencing at the level of protein (e.g., removal of existing proteins), thus serving as a protein analog to CRISPR / Cas9 and RNAi / RISC, and further to enable sequence-specific silencing of host functions without the modification of the host genome.

Disclosed are novel methods and pharmaceutical compositions for creating tunable, protein target-specific polypeptides, their use for adjustable regulation of the levels of one or more protein targets and associated biological functions thereof, and applications to highly selective detection and / or isolation of one or more protein targets.

The present application relates to natural ferritin, and particularly relates to an intracellular delivery system and application thereof. The system can effectively deliver various proteins into cells and maintain the biological activity thereof, and provides important technical support for the development of protein therapy with intracellular target as core. The method exhibits significant advantages in promoting intracellular protein transport, intracellular protein interaction research and protein level regulation. The delivery system has wide applicability, is simple to operate and safe and reliable, and becomes an important tool for future intracellular protein research and application.

The invention provides a method for detecting the protein state of gene-edited cynoglossus semilaevis Dmrt1, namely a protein immunodetection method based on an antigen and an antibody thereof is established on the basis of designing and obtaining optimized antigen polypeptide capable of specifically recognizing gene-edited derived protein, so that accurate identification and product monitoring of the gene-edited cynoglossus semilaevis are realized. The amino acid sequence of the antigen polypeptide is SEQ ID NO: 2. The optimized antigen capable of specifically recognizing a gene editing product is obtained through design and is used for preparing a high-titer antibody and developing a detection product, so that a method for directly and accurately identifying the gene editing cynoglossus semilaevis at the protein level is established, the defect that the edited protein product cannot be detected in the prior art is overcome, and the detection efficiency is improved. And a key tool is provided for functional verification and biological safety evaluation of the gene editing fish.

Described herein are methods of treatment with myosin inhibitors based on protein levels; methods of monitoring response to treatment based on such protein levels; and methods of determining whether to treat a patient with a myosin inhibitor based on such protein levels. Such methods may include obtaining a biological sample of a subject, measuring one or more protein levels in the sample, analyzing the one or more protein levels, and determining the therapeutic response based on the analysis, and may also include treating the subject based on the determination of a therapeutic response.

Disclosed are methods and pharmaceutical compositions for producing adjustable protein target-specific polypeptides, use for adjustable regulation of the level of one or more protein targets or a family of related protein targets and associated biological functions thereof, use for treating or preventing a disease and / or condition, selective detection and / or isolation of one or more protein targets, and use of studying the function of one or more protein targets using polypeptides that are analogs of gene knockdown by RNA interference or gene knockout by CRISPR / Cas9 in a subject.

The application provides application of a VISTA gene as an early diagnosis marker of primary liver cancer, and belongs to the technical field of biological medicine. The application finds that inhibition of VISTA gene expression can effectively inhibit the proliferation and clone formation of liver cancer, and overexpression of the VISTA gene can significantly enhance the proliferation and clone formation of liver cancer. BRD4 is an upstream regulator of VISTA, and after overexpression of BRD4, the VISTA protein level is obviously increased, and after knockdown of BRD4, the VISTA protein level is obviously decreased. MMP11 is a downstream substrate of VISTA, and VISTA regulates MMP11 at the transcriptional level and the protein level, and after overexpression of VISTA, the expression level of MMP11 is obviously increased, and after knockdown of VISTA, the expression level of MMP11 is obviously decreased. BRD4 regulates the mRNA transcription of MMP11 by regulating the expression of VISTA, and then affects the occurrence of primary liver cancer.

The present invention relates to a method for specifically degrading KRAS mutant (G12V) by treating a cell line expressing KRAS mutant (G12V) with a complex of a RAS binder that specifically binds to KRAS mutant (G12V) and an E3 ligase (E3 ligase) NEDD4 HECT, and a composition for use in the method. It can be confirmed that the method developed in the present invention, when treating a cell line expressing KRAS wild type, KRAS wild type is not degraded, in a KRAS mutant (G12V) cell line, the protein level is decreased, the ERK activity is inhibited, and the proliferation, penetration of cancer cells related to KRAS mutant (G12V) is inhibited.

The present invention relates to several biomarkers, including IL-1RA, IFN-γ and GM-CSF, whose expressions at the mRNA level and at the protein level, correlate with chronic pathologies, such as Lyme disease, in particular the late chronic form of Lyme disease. More specifically, the invention provides methods and kits for the diagnosis of such chronic pathologies and for the assessment of a patient's response to a treatment, as well as methods and therapeutic agents for the treatment of such chronic pathologies.

The invention provides a method of detecting or predicting a relapse of multiple sclerosis in an individual having a form of multiple sclerosis, comprising: (a) providing a blood sample of the individual; (b) testing the blood sample to determine a protein activity or protein level, wherein the protein is Factor VIII, von Willebrand Factor, or Protein C; and (c) detecting or predicting a relapse of multiple sclerosis in the individual if the protein activity or protein level is elevated compared to the protein activity or protein level in an individual not having the form of multiple sclerosis and the patient's own baseline value. The invention also provides a method of treating an individual having multiple sclerosis who is experiencing a relapse or is predicted to experience a relapse, comprising treating the individual by administering a dose of a steroid or an anticoagulant compound effective to reduce symptoms of multiple sclerosis.

The present application relates to a SIGMA-based method, system and device for predicting the pathogenicity of mutations. The method comprises the following steps: obtaining mutations of a gene to be predicted; mapping the mutations of the gene to be predicted onto a protein structure of the gene to be predicted to obtain a protein structure with the mutations mapped; extracting features of the protein structure with the mutations to obtain mutation protein structure features; and inputting the mutation protein structure features into a SIGMA model to obtain a classification result of whether the mutations are pathogenic mutations or benign mutations. The mutation protein structure features include protein level features, residue level features and mutation level features. The method predicts the pathogenicity of mutations based on the SIGMA model and mutation protein structure features, explores the high prediction capability and potential application value of the pathogenicity of mutations, and has a beneficial promoting effect on the analysis and research of the pathogenicity of mutations of gene data.

Disclosed herein are a system and method for detecting the interaction between active probes and proteins, suitable for screening candidate ligands of target proteins (biomolecules) in the context of living cells, which overcome the disadvantages of traditional ligand screening methods that require modification or purification of target proteins, representing an in situ quantitative screening technology. Additionally, the method of the present invention exhibits high versatility, being applicable to the screening of inhibitors, agonists, synergistic ligands, and degraders capable of altering protein abundance. By combining detection methods such as ELISA and qPCR, it can sensitively and quantitatively reflect interactions between proteins and ligands or changes in protein levels. This method is broadly applicable to drug lead compound screening, protein functional studies, and other biomedical research fields. Further disclosed herein use of the method of the present disclosure in detecting antigens by a combination of a specific probe and antibody in in vitro diagnostics (IVD), and in screening specific probes as reagents for use in IVD.

The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as low. The invention is also directed to methods of performing an ELISA, including sequential steps of contacting a solid surface with a plurality of solutions each comprising in turn a capture antibody, a blocking agent, a sample suspected of containing an analyte, a detection antibody and an enzyme conjugate, in which the solid surface is subjected to a wash process after each sequential step.

This specification provides a method for providing information on metachronous recurrence of gastric cancer, the method comprising: measuring the mRNA or protein level of at least one marker gene among CD8, CD4 and PD-L1 in a biological sample isolated from an individual; and determining the likelihood of metachronous gastric cancer recurrence in an individual based on the measured mRNA or protein level of the marker gene.